| Cash and cash equivalents |
33.12M |
| Investments in marketable securities |
179.28M |
| Receivable due from GSK |
| Prepaid expenses and other current assets |
| Total current assets |
221.71M |
| Property and equipment, accumulated depreciation and amortization of $8,095 and $8,959 at December 31, 2010 and June 30, 2011, respectively |
10.18M |
| Other non-current assets |
1.79M |
| Total Assets |
918.18M |
| Accounts payable and accrued expenses |
29.01M |
| Current portion of capital lease obligations |
| Current portion of deferred revenue |
| Current portion of secured loan |
| Total current liabilities |
85.61M |
| Deferred revenue, less current portion |
| Warrant liability |
| Secured loan, less current portion |
| Commitments and contingencies |
0 |
| Common stock, $.01 par value, 50,000,000 shares authorized, 34,508,932 shares issued and outstanding at December 31, 2010, 50,000,000 shares authorized, 34,596,809 shares issued and outstanding at June 30, 2011 |
1.48M |
| Additional paid-in capital |
1.04B |
| Accumulated other comprehensive loss |
| Deficit accumulated during the development stage |
-720.96M |
| Total stockholders' equity |
336.56M |
| Total Liabilities and Stockholders' Equity |
918.18M |
